Abstract Background Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favorable effects on cardiorenal outcomes in patients with predominantly stage 3 or 4 chronic kid...
Covid-Induced Changes in Health Care Delivery The rapid pace of delivery-system change during the pandemic revealed the limitations of new delivery modes and raises questions about whether our curr...
Abstract Background The role of direct oral anticoagulants as compared with vitamin K antagonists for atrial fibrillation after successful transcatheter aortic-valve replacement (TAVR) has not been...
Population Health and Human Rights The way a society protects and promotes human rights shapes public policies, determines the distribution of resources and access to services, and ultimately affec...
#1Julia Adler-Milstein(UCSF: University of California, San Francisco)H-Index: 31
#2Ateev Mehrotra(UCSF: University of California, San Francisco)
Paying for Digital Health Care After a substantial investment in information technology, providing digital health care is technically feasible. But patients and physicians can’t reap the benefits b...
Prolonged dual antiplatelet therapy is the treatment of choice for patients with an acute coronary syndrome who have undergone percutaneous coronary intervention (PCI) with a drug-eluting stent.1,2...
Abstract Background The appropriate duration of dual antiplatelet therapy in patients at high risk for bleeding after the implantation of a drug-eluting coronary stent remains unclear. Methods One ...
#1Mark H. Drazner(UTSW: University of Texas Southwestern Medical Center)H-Index: 62
More Evidence for SGLT2 Inhibitors in Heart Failure Mark Drazner comments on the findings of the EMPEROR-Preserved trial, which assessed the potential benefit of empagliflozin in patients with a pr...
Empagliflozin and Renal Outcomes in Heart Failure In a planned pooled analysis of two trials that evaluated empagliflozin in patients with heart failure, major adverse renal outcomes occurred in 2....
Abstract Background Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects ...